Abstract. Identification of novel botanicals that can selectively induce apoptosis and arrest growth of cancer cells without producing cytotoxic effects is highly appreciable for cancer therapy. The present study aimed to investigate the possibility of acetylbritannilactone (ABL) derivative 5-(5-(ethylperoxy) pentan-2-yl)-6-methyl-3-methylene-2-oxo-2,3,3a,4,7,7a-hexahydroben-zofuran-4-yl2-(6-methoxynaphthalen-2-yl) propanoate (ABL-N) as a therapeutic agent in human prostate cancer and potential mechanisms. Human prostate cancer cells were treated with ABL-N of different concentrations (0, 5, 10, 20, 30 and 40 µmol/l). Cell viability, migration and apoptosis were determined. Activities of caspases were assayed, as well as protein expression of cancer-related proteins KLF5, Stat5b and ICAM-1 in PC3 cells. The therapeutic effect of ABL-N was further evaluated in our tumor xenografts. ABL-N inhibited growth of prostate cancer cells in a dose-dependent manner, without obvious effect on normal human prostate epithelial PrEC cells. ABL-N administration induced apoptosis of PC3 cells in a dose-dependent manner, along with the enhanced activity of caspases and increased Bax/Bcl-2 ratio. Expression of KLF5, Stat5b and ICAM-1 was significantly downregulated in PC3 cells. Our in vivo study further confirmed that ABL-N significantly inhibited the tumor growth of PC3 cells in the xenograft mouse model. ABL-N induces apoptosis of prostate cancer cells through activation of caspases, increasing the ratio of Bax/Bcl-2, as well as suppression of KLF5, Stat5b and ICAM-1 expressions. The present study indicated that ABL-N may be a potential therapeutic drug for human prostate cancer, and our data supported further studies to explore the therapeutic potential of ABL-N in other types of human cancer.
Introduction
Prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths in many Western countries. It accounts for 27%/233,000 of incident cases in the US alone with a total of 29,480 predicted deaths, according to cancer statistics reported by the American Cancer Society in 2014 (1) . The incidence of prostate cancer in Asian population, including the Chinese, has been increasing in recent years, although still lower than that of Western countries (2, 3) . The incidence of prostate cancer is known to increase with advancing age, and it inevitably becomes an increasingly greater problem as life expectancy is globally improving.
Apoptosis is an important process in a wide variety of biological systems, including cell development and maintenance of tissue homeostasis, and is well documented to play an essential role as a protective mechanism against carcinogenesis (4). In prostate cancer, a fine balance between cell proliferation and apoptosis is lost contributing to the increased cellular mass and tumor progression (5) . Intervention using cancer chemopreventive compounds has shown a promising opportunity for preventing or slowing the progression of this downloaded disease (6) . Increasing attention has been focused on the utilization of naturally occurring botanicals or dietary substances for prostate cancer therapy (7) (8) (9) . In this regard, for prostate cancer chemoprevention at the present time, there is considerable emphasis in identifying novel botanicals that selectively induce apoptosis and growth arrest of prostate cancer cells without producing cytotoxic effects on normal cells.
Acetylbritannilactone (ABL) is a sesquiterpene lactone abundant in Inula Britannica L, a traditional Chinese medicinal herb (Xuan Fu Hua). It has been reported to have chemopreventive properties by inducing cell apoptosis in breast and ovarian cancers (10, 11) . We have recently synthesized a derivative compound of ABL, 5-(5-(ethylperoxy) pentan-2-yl)-6-methyl-3-methylene-2-oxo-2,3,3a,4,7,7a-hexah ydrobenzofuran-4-yl2-(6-methoxynaphthalen-2-yl) propanoate (ABL-N; Fig. 1A ). Our previous study indicated that ABL-N treatment causes a significant inhibition of tumor growth in vivo and ABL-N induces apoptosis in breast cancer cells through the activation of caspases and JNK signaling pathways, suggested that ABL-N may be a potential drug for breast cancer prevention and intervention (12) . However, the antitumor activity and the molecular targets of ABL in prostate cancer cells have not been determined. In the present study, we investigated the antiproliferative and pro-apoptotic effects of ABL-N, as well as the expression of apoptosis-related proteins in ABL-induced growth suppression of human prostate cancer cells and the xenograft mouse model.
Materials and methods
Cell lines. The human prostate cancer cells PC3, DU145 and LNcap, were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and were routinely cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) (both from Invitrogen, Carlsbad, CA, USA), 4 mmol/l glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. The normal epithelial prostate cells PrEC were obtained from Clonetics-BioWhittaker, Inc. (Walkersville, MD, USA), were cultured in prostate epithelial basal medium with PrEgM BulletKit (both from Clonetics). All cells were incubated at 37˚C and 5% CO 2 in a humid environment and subcultured twice a week.
ABL-N preparation. ABL-N was prepared as described in our previous study (12) . The purity and chemical structure of ABL-N were certified by melting point, elemental analysis and spectral studies. The purified ABL-N was dissolved in ethanol using ultrasonication. The effects of ABL-N on our experiments were compared with those of ethanol at a final concentration of 0.5% as vehicle.
MTT assay. The PC3, DU145, LNcap and PrEC cells were seeded into 96-well plates at a density of 4,000/well and were cultured for 24 h. Cells were then treated with ABL-N of different concentrations (0, 2.5, 5, 10, 15, 20, 25, 30, 35 and 40 µM). After 24 h of incubation, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent, 5 mg/ml in phosphate-buffered saline (PBS) was added to each well (20 µl/well) followed by incubation for 4 h at 37˚C, and then the plate was centrifuged at 1,000 rpm for 5 min at 4˚C. After careful removal of the medium, formazan crystals were dissolved in 0.1 ml buffered dimethylsulfoxide (DMSO; Sigma), and the absorbance was read on a microplate reader at the wavelength of 570 nm. Absorbance values were normalized to the values obtained from the vehicle-treated cells. Taking into account the more aggressive and highly metastatic nature of prostate cancer, PC3 cells were selected as a model system to conduct further experiments.
Wound migration assay. Confluent PC3 cells grown in 10 cm 2 dishes were wounded using sterile pipette tips, washed twice with 1X PBS, and grown in RPMI-1640 medium (Invitrogen) supplemented with 10% FBS and various concentrations of ABL-N for 24 h. Then PC3 cells were photographed under a phase-contrast microscope (magnification, x10).
Apoptosis assays. Apoptosis of PC3 cells was firstly determined using terminal deoxynucleotidyl transferasemediated nick-end labeling (TUNEL) kit (DeadEnd Fluorometric TUNEL System; Promega, Madison, WI, USA) after cultivation with different concentrations of ABL-N for 24 h. Cells were fixed in 4% paraformaldehyde in PBS for 25 min at 4˚C. After permeabilized in 0.1% Triton X-100 in PBS for 5 min on ice, the samples were incubated in TUNEL reaction mixture for 1 h at 37˚C in a dark and humidified atmosphere.
For nuclear staining, the fixed cells were placed on slides and stained with 1 mg/ml DAPI for 15 min. After three washes, images were captured immediately using a digital camera attached to the fluorescence microscope.
For quantification of apoptosis by flow cytometry, PC3 cells were grown at a density of 70-80% confluency and treated with different concentrations of ABL-N for 24 h. The cells were trypsinized, washed with PBS and were processed for labeling with Annexin V and propidium iodide (PI) using an Annexin V-FLUOS staining kit (Roche Diagnostic Corporation) according to the manufacturer's protocol. The labeled cells were analyzed by flow cytometry (Becton-Dickinson, San Jose, CA, USA).
Caspase activity assay. The activities of caspase-2, -3, -6 and -8 were separately assayed using the respective Caspase-glo assays (Promega) according to the manufacturer's protocol. Briefly, cells were solubilized with lysis buffer for fluorometric assay. After incubation at 37˚C for 1 h, the caspase-2, -3, -6 and -8 activities were monitored by measuring the fluorescence at 460 nm. Each sample was measured in triplicates.
Western blot analysis. PC3 cells were treated with ABL-N, harvested and lysed. Equal amounts of cell extracts were separated using SDS-PAgE and transferred to a PVDF membrane. The protein was visualized using the enhanced chemiluminescence kit (Amersham Biosciences) as previously described (13) .
Tumor xenograft experiments. The 4-week-old athymic male nude mice (BALB/c) were purchased from the Vital River Laboratory Animal Technology Co., Ltd. [certificate no. SCXK (Jing) 2007-0001]. An aliquot of 1x10 6 PC3 cells suspended in 50% Matrigel were implanted subcutaneously into both flanks of each BALB/c mouse. Six days after tumor cell inoculation, small tumors were identified. Animals were randomly divided into experiment and control groups (n=6), ABL-N (15 mg/kg body weight) or an equal volume of the vehicle was intraperitoneally injected, respectively. Tumor growth was assessed every other day by caliper measurement and tumor volume was estimated by the formula width 2 x length x 1/2. At the time of sacrifice, tumors were excised and a portion fixed in 10% buffered formalin for 24 h for immunohistochemical studies. The animal study was approved by the Ethics Committee for animal research of Hebei Medical University. All the animals were bred and maintained in the Specific Pathogen Free Animal Care Facility. The National Institutes of Health guidelines for the care and use of laboratory animals were followed in all animal procedures.
Immunohistochemistry. Portions of the dissected mouse tumors were immediately fixed in 10% neutral buffered formalin for 24 h at room temperature after harvesting, and were then placed in 70% ethanol. Formalin-fixed tissues were embedded in paraffin, sectioned at 5 µm and incubated with the specific antibodies against Stat5b, KLF5, ICAM-1, Bcl-2 and Bax (Santa Cruz Biotechnology) for 1 h at room temperature, followed by biotinylated secondary antibodies for 30 min at room temperature. Sections were counterstained with hematoxylin. The specimens were viewed with an Olympus BX51 microscope. Staining intensities were determined by measurement of the integrated optical density (IOD) with light microscopy using a computer-based Image-Pro Morphometric system. Measurements were conducted by two independent observers in a double-blind manner.
Statistical analysis. Data are expressed as the means ± SE. ANOVA and the paired or unpaired t-test was performed for statistical analysis as appropriate. p<0.05 was considered to indicate a statistically significant result.
Results

ABL-N inhibits the cell viability of PC3, DU145 and LNCap cells.
MTT assay showed that ABL-N suppressed the cell viability of human prostate cancer cells (PC3, DU145 and LNcap) in a dose-dependent manner (Fig. 1B) , with similar IC 50 values obtained 24 h after ABL-N treatment (Fig. 1C) . However, the survival of normal human prostate epithelial PrEC cells was minimally affected by ABL-N treatment, even at high concentrations (40 µmol/l) that were highly cytotoxic to the prostate cancer cells (Fig. 1B) .
ABL-N inhibits the cell migration of PC3 cells.
According to the experimental results of MTT, the final concentrations of 0, 5, 10, 20 and 40 µmol/l were used for ABL-N treatment in the further experiments. In the wound-healing assay, ABL-N treatment significantly decreased wound healing of PC3 cells in a dose-dependent manner when compared with the control cells ( Fig. 1D and E) .
ABL-N induces apoptosis of PC3 cells.
To investigate whether ABL-N reduced cell viability involving the induction of cell apoptosis, we conducted flow cytometric analysis and TUNEL assay of ABL-N-treated PC3 cells. As shown in Fig. 2 , in the cells treated with ABL-N, the percentage of cells stained positive for Annexin V and negative for PI was significantly increased after ABL-N treatment, even at the lower concentrations. The number of Annexin V and PI-positive cells was significantly increased at higher concentrations of ABL-N (20 and 40 µmol/l, Fig. 2A ). Cells were further stained for TUNEL and DAPI to assess the effects of ABL-N on apoptosis, results showed enhanced apoptosis of PC3 cells after exposure to ABL-N, and the condensed and fragmented nuclei increased with ABL-N treatment (Fig. 2B) .
ABL-N induces the activities of caspases in PC3 cells.
To test whether caspases were involved in the ABL-N-induced apoptosis, the activities of caspase-2, -3, -6 and -8 were colorimetrically assayed. As shown in Fig. 2C , caspase-3 activity was significantly increased after ABL-N treatment and was dose-dependent. The activities of caspase-8 and -9 were also enhanced to some extent, while this effect was less significant than that of the caspase-3. By contrast, caspase-2 and -6 activities were not significantly influenced by ABL-N treatment, even at the high concentration of 40 µmol/l (Fig. 2C) .
ABL-N inhibits cancer-related proteins in PC3 cells.
Western blotting was performed to investigate the expression of cancer-related proteins Stat5b and Klf5 and pro-angiogenic factor ICAM-1 in ABL-N-treated PC3 cells. As shown in Fig. 3A , ABL-N treatment significantly decreased the expression of Stat5b, KLF5 and ICAM-1, and this effect was enhanced with the increasing concentration of ABL-N (p<0.05).
ABL-N treatment results in an elevated Bax/Bcl-2 ratio in PC3 cells.
The ratio of Bax/Bcl2 is often considered as a decisive factor in cell apoptosis or survival. As shown in Fig. 3B , the exposure of human PC3 cells to ABL-N caused a marked increase in Bax protein expression, while the levels of Bcl-2 protein were not obviously affected after ABL-N treatment. This resulted in a substantial increase in Bax/Bcl-2 ratio, which favors apoptosis and collectively forms a molecular basis for the apoptotic action of ABL-N (Fig. 3B) .
ABL-N inhibits the growth of prostate cancer in vivo.
The xenograft models of PC3 cells were established in 
Discussion
Recently, the apoptosis signaling systems have been shown to provide promising targets for development of novel anticancer agents (14) . Several plant-derived bioactive agents, such as delphinidin, baicalein, gambogic acid and green tea, are known as chemopreventive agents and have been reported to induce apoptosis in a number of experimental models of carcinogenesis (15) . Induction of apoptosis is therefore considered as a possible therapeutic mechanism of these chemopreventive agents. ABL, which has been shown to be potently antitumorigenic, has pro-apoptotic features in numerous carcinoma cell types (11, 16) . We recently obtained a highly active derivative ABL-N, which has shown exceptional antiproliferative activity in human breast cancer cells (12) . The aim of the present study was to investigate the possible role of ABL-N-induced apoptosis in human prostate cancer cells and delineate the potential mechanism.
Our results showed that ABL-N inhibited the cell viability of human prostate cancer cell lines LNCaP, DU145 and PC3 at low concentration, and after increased treatment with 20 µM or more of ABL-N, there was a pronounced accumulation of apoptotic cells. By contrast, cell viability of normal human prostate epithelial PrEC cells was not significantly influenced by ABL-N even at high concentration, indicating that ABL-N selectively induced apoptosis and arrested growth of prostate cancer cells without producing cytotoxic effects on normal cells. Studies in our laboratories have previously reported the death of different human breast cancer cell lines induced by ABL-N, and this effect has been linked to caspase-dependent apoptosis (12) . Results of our TUNEL and DAPI assays demonstrated that ABL-N induced apoptosis in PC3 cells. The number of Annexin V and PI-positive cells increased with higher concentrations of ABL-N, indicating an activation of the pro-apoptotic pathway with consecutive apoptotic cell death. In the quantification of apoptosis by flow cytometry experiments, the number of the cells actively undergoing apoptosis during ABL-N exposure was determined to investigate the sensitivity of prostate cancer cells to ABL-N-induced apoptosis. After exposure to 40 µmol/l ABL-N, however, the late apoptotic/necrotic cells predominated with high proportion of 65% compared with that of 15% for early apoptotic cells, indicating the accelerated cell death induced by ABL-N treatment.
Caspases are known as key mediators of apoptosis and contributed to the apoptotic morphology through the cleavage of various cellular substrates. Caspase-3 is an executioner caspase that can be activated by a mitochondrial pathway involving activation of caspase-9 due to release of cytochrome c to the cytosol or a death receptor pathway involving caspase-8 (17) . In the present study, the results that caspase-3 activation enhanced markedly indicated that caspase-3 plays a key role as an important executioner in ABL-N-induced apoptosis in PC3 cell lines. Moreover, the results of the present study indicated that ABL-N-induced apoptosis in PC-3 cells is probably mediated by both caspase-9 and caspase-8. Consequently, we hypothesized that mitochondria or death receptor-mediated activation of the caspases may be a potential mechanism underlying ABL-N-induced apoptosis in prostate cancer cells and further study was performed.
Bcl-2 family has been shown to play an important regulatory role in apoptosis, either as activator (Bax) or as inhibitor (Bcl-2) (14, 18) . Bax exerts pro-apoptotic activity by translocation from the cytosol to the mitochondria, where it induces cytochrome c release, while Bcl-2 exerts its anti-apoptotic activity, at least in part by inhibiting the translocation of Bax to the mitochondria (19, 20) . The Bcl-2 and Bax protein ratio has been recognized as a key factor in regulation of the apoptotic process (14, 21) . They can activate or inhibit the release of downstream factors such as cytochrome c which leads to the activation of caspase-3 and PARP in the execution of apoptosis (22) . The results of the present study indicated that ABL-N-induced apoptosis in human PC3 cells was accompanied by upregulation of Bax, yet with no marked downregulation effect on Bcl-2 protein expression. Signal transducer and activator of transcription 5a and 5b (Stat5a/b) is critical for the viability of human prostate cancer cells, and it is activated in prostate cancer, yet not in normal human prostate epithelium (23) . The activation of Stat5a/b in primary prostate cancer predicted early prostate cancer recurrence (24) . It has been reported that active Stat5 promoted migration and invasion of prostate cancer cells, induced re-arrangement of the microtubule network and increased metastases formation of prostate cancer cells (25,26). Pro-angiogenic factor ICAM-1 has been reported to provide a structural and functional interface between epithelial cells and the extracellular environment, and the expression of ICAM-1 in PC3 cells was correlated with increased metastatic potential of prostate cancer cells (27) . Herein, we also showed that expression of ICAM-1 and Stat5b was significantly decreased in highly metastatic PC-3 prostate cancer cells treated with ABL-N.
KLF5 is a basic transcriptional factor that functions in multiple cellular processes including cell proliferation, differentiation and apoptosis, and it has both pro-and antitumorigenic effects (28) . KLF5 is thought to be a tumor suppressor in prostate and breast cancers (29, 30) , while it has also been shown to drive proliferation in cultured cells and to be a prognostic factor for the survival of patients with breast cancer (31) . Studies that examine KLF5 expression by stage reflected high KLF5 expression in early stages of cancer progression and lower KLF5 expression in later stages (32, 33) . Our results showed that ABL-N apparently decreased the protein expression of KLF5 in a dose-dependent manner. Thus, KLF5 also plays a promoting role in the process of prostate cancer progression. Accordingly, we hypothesized that ABL-N antitumor effect is possibly through inhibiting these factors and further study was needed to demonstrate this effect.
We next used an experimental model of prostate cancer to further evaluate the antitumor effect of ABL-N and the potential mechanism. The findings of our in vivo study confirmed the antitumor activity of ABL-N against the PC3 human xenografts, a widely accepted model of highly aggressive prostate cancer. Administration of ABL-N for only 12 consecutive days inhibited the growth of established PC3 tumors when compared with that of the vehicle-treated ones. ABL-N treatment did not result in significant changes in body weights and histologic data in nude mice. Corroborating the results in vitro, our in vivo study also demonstrated the upregulated expression of Bax and increased Bax to Bcl-2 ratio, as well as the decreased expression of cancer-related proteins KLF5, Stat5b and pro-angiogenic factor ICAM-1. The present study provided clear experimental evidence that ABL-N exerted therapeutic and preventive effects on prostate cancer without notable toxicity, and it acts through suppression of KLF5, ICAM-1 and Stat5b expression and upregulation of Bax/ Bcl-2 ratio. All the above results indicated that ABL-N may be a promising candidate for cancer therapy, although further experimental studies should be performed to demonstrate the therapeutic potential of ABL-N in other types of cancer and the functional mechanism.
To the best of our knowledge, this is the first study detailing apoptosis induction of ABL-N in prostate cancer cell PC3 in vivo and in vitro. Our results indicated that ABL-N inhibited proliferation of PC-3 cells at least partly by causing apoptosis through suppressing the cancer-related protein Stat5b, Klf5 and ICAM-1, and increasing Bax/Bcl-2 ratio indicating that ABL-N may be developed as a potential anticancer agent against human prostate cancer. The present study offers new therapeutic perspective to prostate cancer therapy, and our data also support further studies to explore the therapeutic potential of ABL-N in other types of human cancer.
